Level C· Early human research exploring benefitsProspective StudyEurope PMC

Necdin-E2F4 interaction provides insulin-sensitizing effect after weight loss induced by gastric bypass surgery

Pamuklar ZN., Chen J., Muehlbauer M., Spagnoli A., Torquati A.

Prospective Study on Type 2 Diabetes, published in Surg Obes Relat Dis (2013) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Surg Obes Relat Dis (2013)
Reported sample size
—
Source database
Europe PMC
PMID
22138333
PMCID
PMC3302937
DOI
10.1016/j.soard.2011.10.014
Citations
2

Abstract (original English)

Background The insulin-like growth factor-1 (IGF-1) signaling pathway promotes adipocyte differentiation and, therefore, insulin sensitivity by suppression of necdin expression, which represses peroxisome proliferator-activated receptor-gamma promoter activity by interaction with E2F4 in mouse adipocytes. The aim of the present study was to test the hypothesis that this pathway represents one of the mechanisms by which Roux-en-Y gastric bypass surgery (RYGB) induces resolution of insulin resistance. Methods Clinical samples were collected and the key biomarkers measured to test the hypothesis that the IGF-1 pathway represents 1 of the mechanisms by which RYGB induces resolution of insulin resistance in obese individuals. Results Free IGF-1 levels were significantly greater in the post-RYGB patients than in the pre-RYGB obese patients (2.55 ± 1.54 versus 1.32 ± .65 μg/L, P = .03) and similar to that in normal weight controls (2.54 ± 1.27 μg/L). Necdin and E2F4 gene expression in the adipose tissue was significantly downregulated after RYGB compared with obese and were similar to the levels observed in the controls. In mature human adipocytes cultured in vitro, treatment with des-IGF-1 induced downregulation of necdin and E2F4 gene expression in a dose-dependent manner (P = .01). Conclusion After RYGB, the insulin/IGF-1 signaling pathway is activated and could account for the obs

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
Cells, CulturedAdipocytesHumansInsulin ResistanceObesity, MorbidWeight LossNerve Tissue ProteinsNuclear ProteinsGastric BypassCase-Control Studies

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research